Dr. Douglas Craig Distefano, MD

Dr. Distefano practices at The Mount Sinai Hospital in New York, New York, part of Mount Sinai Health System.

Dr. Distefano's NPI, 1487795225, was assigned on February 12, 2007. Dr. Distefano graduated from New York University Grossman School of Medicine in 1974. Dr. Distefano holds New York license 127858.

Dr. Distefano's primary practice is The Mount Sinai Hospital, at One Gustave L Levy Place, New York, NY 10029 in New York County. The practice phone is (212) 241-7981. Dr. Distefano also practices at The Mount Sinai Hospital, 1 Gustave L Levy Pl, New York, NY 10029.

Dr. Distefano's primary practice is The Mount Sinai Hospital in New York, New York, part of Mount Sinai Health System. The medical group on file is Mount Sinai Institute for Liver Medicine. Dmand AI also links Dr. Distefano to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Distefano practices, 2 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Distefano's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Distefano is licensed in New York.

CMS data shows 2,215 Medicare services from Dr. Distefano across 7 procedure codes in 2024, for 808 Medicare patients. Medicare paid $74,849 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 808 Medicare patients who saw Dr. Distefano in 2024. The largest group is 75 to 84, with 311 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 25% are also on Medicaid. Their average risk score is 2.17, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Distefano's median patient age at 73, with 57% women.

In 2024, Dr. Distefano wrote 5,952 Medicare Part D claims for 630 patients. 84% of them were for generic drugs. CMS names the drug for 5,462 of them, across 68 drugs with 11 or more claims each, at $834,426 in total drug cost. In 2023, CMS named 5,357 claims across 67 drugs.

Dr. Distefano accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 30 general payments to Dr. Distefano from 5 drug and device companies from 2016 to 2021. Consulting fees make up the largest share, 92% of the total. Daiichi Sankyo Inc. paid the most, $8,000. It also lists 2 research payments totaling $2,000 in 2017.

Dr. Distefano graduated from New York University Grossman School of Medicine in 1974.